Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?

REFERENCES

• WHITE M, RACINE N, DUCHARME A, DE CHAMPLAIN J: Therapeutic potential of angiotensin II antagonists. Expert Opin. Investig. Drugs(2001) 10:1687–1701.
   PubMed Web of Science ®Google Scholar
• UNGER T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. (2002) 89(2A):3A–10A.
   Google Scholar
• LABINJOH C, NEWBY DE, PELLEGRINI MP, JOHNSTON NR, BOON NA, WEBB DJ: Potentiation of bradykinin-induced release by angiotensin-converting enzyme inhibition.' Am. Coll. Cardiol. (2001) 38:1402–1408.
   PubMedGoogle Scholar
• GAINER JV, MORROW JD, LOVELAND A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl. I Med. (1998) 339:1285–1292.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• •Major trial showing similar outcomes in hypertension with captopril and 13-adrenoceptor blockers or calcium channel blockers.
   Google Scholar
• HANSSON L, LINDHOLM LH, EKBOM T et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751–1756.
   Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. I Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• •Important trial showing cardioprotective effects of ramipril are independent of blood pressure lowering.
   Google Scholar
• MATHEW J, SLEIGHT P, LONN E et al: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 104:1615–1621.
   PubMed Web of Science ®Google Scholar
• COHEN A, BREGMAN B, AGABITI ROEI E et al.: Comparison of irbesartan versus felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left Ventricular hypertrophy Regression. I Hum. Hypertens. (1998) 12:479–483.
   Google Scholar
• DAHLOF B, DEVEREUX RB, DE FAIRE U et al: The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am. .1 Hypertension (1997) 10:705–713.
   PubMed Web of Science ®Google Scholar
• JULIUS S: Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology (1999) 91\(Suppl. 1):8–13.
   Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23:995–1003.
   Google Scholar
• •Recent trial showing AT-I antagonism is more beneficial that 13-blockade in hypertension with hypertrophy.
   Google Scholar
• DE ROSA ML, CARDACE P, ROSSI M, BAIANO A, DE CRISTOFARO A: Comparative effects of chronic ACE inhibition and AT1 receptor blocker losartan on cardiac hypertrophy and renal function in hypertensive patients.' Hum. Hypertens. (2002) 16:133–140.
   PubMed Web of Science ®Google Scholar
• CUOCOLO A, STORTO G, IZZO R et al.: Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. I Hypertens. (1999) 17:1759–1766.
   PubMed Web of Science ®Google Scholar
• HIROOKA Y, IMAZUMI T, MASAKI H et al.: Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension (1992) 20:175–180.
   PubMed Web of Science ®Google Scholar
• VON ZUR MUHLEN B, KAHAN T, HAGG A, MILLGARD J, LIND L: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. Hypertens. (2001) 19:1813–1818.
   Google Scholar
• SCHIFFRIN EL, PARK JB, PU Q: Effectof crossing over hypertensive patients from a 13-blocker to an angiotensin receptor antagonist on resistance artery structure and endothelial function. Hypertens. (2002) 20:71–78.
   Google Scholar
• LACOURCIERE Y, BRUNNER H, IRWIN R et al: Effects of modulators of the renin-angiotensin-aldosterone system on cough. Hypertension (1994) 12:1387–1393.
   Google Scholar
• TIKKANEN T, OMVID P, JENSEN HA: Comparison of the angiotensin II antagonist losartan with angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Hypertension (1995) 13:1343–1351.
   Google Scholar
• MIMRAN A, RUILOPE L, KERWIN L: A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose rang of enalapril for the treatment of mild-to-moderate hypertension. Hum. Hypertens. (1998) 12:203–208.
   PubMed Web of Science ®Google Scholar
• ROCA-CUSACHS A, OIGMAN W, LEPE L, CIFKOVA R, KARPOV YA, HARRON DW: A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol (1997) 52:395–506.
   Google Scholar
• MCINNES GT, O'KANE KP, ISTAD H, KEINANEN-KIUKAANNIEMI S, VAN MIERLO HF: Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. Human Hypertens. (2000) 14:263–269.
   PubMedGoogle Scholar
• BREMNER AD, BAUR M, ODDOU-STOCK P, BODIN F: Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin. Exp. Hypertens. (1997) 19:1263–1285.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y: The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int. .1. Clin. Prac. (1999) 53:99–103.
   Google Scholar
• WURZNER G, GERSTER JC, CHIOLERO A et al.: Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. Hypertens. (2001) 19:1855–1860.
   Google Scholar
• SCHMIDT A, GRUBER U, BOHMIG G, KOLLER E, MAYER G: The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial. Transplant (2001) 16:1034–1037.
   PubMed Web of Science ®Google Scholar
• MIGHELLI G, SEYDOUX C, GOY JJ, BURNIER M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation (1998) 66:268–271.
   PubMedGoogle Scholar
• AGODOA LY, APPEL L, BAKRIS GL et al.: Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA (2001) 285:2719–2728.
   PubMed Web of Science ®Google Scholar
• •Recent trial showing ramipril is beneficial in hypertensive nephrosderosis in African-Americans.
   Google Scholar
• STERGIOUS GS, SKEVA II, BAIBAS NMet al.: Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. Cardiovasc. Pharmacol (2000) 35:937–941.
   Google Scholar
• WAEBER B, ASCHWANDEN R, SADECKY L, FERBER P: Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. Hypertension (2001) 19:2097–2104.
   Google Scholar
• NISKANEN L, HEDNER T, HANSSON L, LANKE J, NIKLASON A: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/P-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care (2001) 24:2091–2096.
   PubMed Web of Science ®Google Scholar
• LINDHOLM LH, IBSEN H, DAHLOF B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:1004–1010.
   PubMed Web of Science ®Google Scholar
• HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• NIELSEN FS, SATO A, ALI S et at Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care (1998) 21:804–809.
   PubMed Web of Science ®Google Scholar
• O'DRISCOLL G, GREEN D, RANKIN J, STANTON F, TAYLOR R: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. j Clin. Invest. (1997) 100:678–684.
   PubMed Web of Science ®Google Scholar
• O'DRISCOLL G, GREEN D, MAIORANA A, STANTON K, COLREAVY F, TAYLOR R: Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. I Am. Coll. Cardiot (1999) 33:1506–1511.
   PubMed Web of Science ®Google Scholar
• CHEETHAM C, COLLIS J, O'DRISCOLL G, STANTON K, TAYLOR R, GREEN D: Losartan, and angiotensin Type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. j Am. Coll. Cardiot (2000) 36:1461–1466.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl. I Med. (1993) 329:1456–1462.
   PubMed Web of Science ®Google Scholar
• •Important trial demonstration renoprotective effect of captopril in type I diabetes
   Google Scholar
• LEWIS JB, BERL T, BAIN RP, ROHDE RD, LEWIS EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am. I Kidney Dis. (1999) 34:809–817.
   PubMed Web of Science ®Google Scholar
• NIELSEN S, HOVE KY, DOLLERUP J et al.: Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetes Obes. Metab. (2001) 3:463–471.
   PubMedGoogle Scholar
• ANDERSEN S, TARNOW L, ROSSINGP, HANSEN BV, PARVING HH: Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney mt. (2000) 57:601–606.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl. j Med. (2001) 345:861–869.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan 352:1252-1256.281:H2150-H2158. in patients with nephropathy due to type 2 diabetes. N Engl. J. Med. (2001) 345:851–860.
   Google Scholar
• •Recent trial showing renoprotective effect of irbesartan in type 2 diabetes.
   Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl. J. Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, BELANGER A, GODIN C et al: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. (2000) 58:762–769.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321:1440–1444.
   PubMed Web of Science ®Google Scholar
• ROSSING K, CHRISTENSEN PK, JENSEN BR, PARVING HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a ramdomized double-blind crossover study. Diabetes Care (2002) 25:95–100
   PubMed Web of Science ®Google Scholar
• MASCHIO G, ALBERTI D, JANIN G: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl. J. Med. (1996) 334:939–945.
   PubMed Web of Science ®Google Scholar
• THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA). Randomised placebo-controlled trial of effects of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet (1997) 349:1857–1863.
   Google Scholar
• •Important trail showing the benefit of ramipril in renal disease without the presence of hypertension.
   Google Scholar
• RUGGENENTI P, PERNA A, GHERARDI G, GASPARI F, BENINI R, REMUZZI G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italian° di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet (1998)
   Google Scholar
• RUGGENENTI P, PERNA A, ZOCCALI C et al.: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: difference between women and men in relation to the ACE gene polymorphism. Gruppo Italian° di Studi Epidemiologici in Nefrologia (Gisen). J. Am. Soc. Nephrol (2000) 11:88–96.
   Google Scholar
• RUGGENENTI P, PERNA A, GHERARDI G et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 354:359–364.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, PERNA A, RENUZZU G: ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to a stop: a post hoc analysis of the REIN trial results. I Am. Soc. Nephrol (2001) 12:2832–2837.
   PubMed Web of Science ®Google Scholar
• MORA-MACIA J, CASES A, CALERO F, BARCELO P: Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure. Nephrol Transplant (2001) 16\(Supp1.1):82–84.
   Google Scholar
• TYLICKI L. RENKE M, RUTKOWSKI P, RUTKOWSKI B; Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: pilot study. Ren. Nutr. (2002) 12:122–125
   PubMedGoogle Scholar
• RUSSO D, MINUTOLO R, PISANI A et al.: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am. I Kidney Dis. (2001) 38:18–25.
   PubMed Web of Science ®Google Scholar
• KINCAID-SMITH P, FAIRLEY K, PACKHAM D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial. Transplant (2002) 17:597–601.
   PubMed Web of Science ®Google Scholar
• RUILOPE LM, ALDIGIER JC, PONTICELLI C et at Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J. Hypertens. (2000) 18:89–95.
   Google Scholar
• DANIELS MCG, KELLER RS, DE TOMBE PP: Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. Am. J. Physiol Heart Circ. Physiol (2001)
   Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N EngL I Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• •Initial trial demonstrating the benefit of an ACE inhibitor after MI.
   Google Scholar
• THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:812–828.
   PubMed Web of Science ®Google Scholar
• KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Eng]. J. Med. (1995) 333:1670–1676.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON F, TORP-PEDERSEN C, KOBER L, HILDEBRANDT P: Effect of angiotensin converting inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. Hypertens. (1997) 15:793–798.
   Google Scholar
• GUSTAFSSON I, TORP-PEDERSEN C, KOBER L, GUSTAFSSON F, HILDEBRANDT P: Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J. Am. Coll. Cardiol (1999) 34:83–89.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, HELD P, KJEKSHUS J,RASMUSSEN K, RYDEN L, WEDEL H: Effects of the early administration of enalapril on mortality with acute myocardial infarction. Results of the Cooperative New Scandinavia Enalapril Survival Study II (CONSENSUS II). N Engl. J. Med. (1992) 327:678–684.
   Google Scholar
• THE CCS-1 INVESTIGATORS: oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet (1995) 345:686–687.
   PubMedGoogle Scholar
• GRUPPO ITALIANO PER LP STUDIO DELLA SOPRAVVINZA NELL'INFARTO MIOCARDICO: GISSI- 3: Effects of lisinopril and transdermal glyceryl trinitrate singly and 6-week mortality and ventricular function after acute myocardial infarction. Lancet (1996) 343:1115–1122.
   Google Scholar
• ZUANETTI G, LATINI R, MAGGIONI AP, FRANZOSI M, SANTORO L, TOGNONI G: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation (1997) 96:4239–4245.
   PubMed Web of Science ®Google Scholar
• FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL COLLABORATIVE GROUP: ISIS-4 a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet (1995) 345:669–685.
   PubMedGoogle Scholar
• AMBROSIONI E, BORGHI C, MAGNANI B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl.' Med. (1995) 332:80–85.
   PubMed Web of Science ®Google Scholar
• BORGHI C, BACCHELLI S, ESPOSTI DD, BIGNAMINI A, MAGNANI B, AMBROSIONI E: Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Am." Hypertens. (1999) 12:665–672.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, GREAVES SC, ARNOLD JM et al.: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation (1997) 95:2643–2651.
   PubMed Web of Science ®Google Scholar
• SPINAR J, VITOVEC J, SPINAROVA L, PLUHACEK L, FISCHEROVA B, TOMAN J: A comparison of intervention with losartan or captopril in acute myocardial infarction. Ear: .1. Heart Fail. (2000) 2:91–100.
   Google Scholar
• DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360(9335):752–760.
   Google Scholar
• •Recent major comparison of captopril and losartan after MI.
   Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl. J. Med. (1987) 316(23):1429–1435.
   PubMed Web of Science ®Google Scholar
• •Initial trial demonstrating the mortality benefit of an ACE inhibitor in heart failure.
   Google Scholar
• HALL AS, MURRAY GD, BALL SG: Follow-up of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction. AIRE Extension (A.T.-_,PPX) Study. Acute Infarction Ramipril Efficacy. Lancet (1997) 349:1493–1497.
   Google Scholar
• DICKSTEIN K, CHANG P, WILLENHEIMER R et al.: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure.j Am. Coll. Cardiol (1995) 26:438–445.
   PubMed Web of Science ®Google Scholar
• RIEGGER GA, BOUZO H, PETR Petal.: Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224–2230.
   Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1587.
   PubMed Web of Science ®Google Scholar
• •Trial showing similar mortality rates with ACE inhibitor and AT1 receptor antagonist in heart failure.
   Google Scholar
• COHN JN, TOGNONI G: A randomizedtrial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. Med. (2001) 345(23):1667–1675.
   PubMed Web of Science ®Google Scholar
• HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99:990–992.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, PFEFFER M GRANGER C et al.: Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. " Card. Fail. (1999) 5:276–282.
   Google Scholar
• YUSUF S: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am.j Cardiol (2002) 89(Suppl.):18A–26A.
   Google Scholar
• DAVIE AP, DARGIE HJ, MCMURRAY JJ: Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation (1999) 20:268–273.
   Google Scholar
• ISRAILI ZH, HALL WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. (1992) 117:234–242.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, ERTL G, KUCH J et al.:Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. (2000) 139:609–617.
   PubMed Web of Science ®Google Scholar
• WARNER KK, VISCONTI JA, TSCHAMPEL MM: Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann. Pliarmacother. (2000) 34:526–528.
   PubMed Web of Science ®Google Scholar
• BARUCH L, ANAND I, COHEN IS, ZIESCHE S, JUDD D, COHN JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation (1999) 99:2658–2664.
   PubMed Web of Science ®Google Scholar
• MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation (1999) 100:1056–1064.
   Google Scholar
• •Trial showing the benefits of ACE inhibition and AT1-receptor antagonist combination in heart failure.
   Google Scholar
• JONG P, DEMERS C, MCKELVIE RS, LIU PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. Am. Coll. Cardiol (2002) 39:463–470.
   PubMed Web of Science ®Google Scholar